• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于真实世界数据评估接种疫苗和既往感染人群中 SARS-CoV-2 感染和住院的风险。

Evaluation of the risk of SARS-CoV-2 infection and hospitalization in vaccinated and previously infected subjects based on real world data.

机构信息

Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

Epidemiologic Unit of the Local Health Authority of Vercelli - Osservatorio Epidemiologico, ASL Vercelli, Vercelli, Italy.

出版信息

Sci Rep. 2023 Feb 3;13(1):2018. doi: 10.1038/s41598-023-28129-7.

DOI:10.1038/s41598-023-28129-7
PMID:36737460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9897610/
Abstract

The objective of our study was to determine the joint protective effect of a previous SARS-CoV-2 infection and vaccination on the risk of a new infection and hospitalization. Two case-control studies nested in a cohort of COVID-19 patients cared for by the Local Health Unit (LHU) of Vercelli, Italy, were performed, one to estimate the risk of infection and the second to estimate the risk of hospitalization. Each new infection and hospitalization was matched with up to 4 disease-free subjects who were the same age, sex and index date (i.e., controls). Study subjects were followed up from cohort entry date to disease outcome, end of follow-up or emigration. Vaccination was associated with a 36% (OR 0.64; 95%CI 0.62-0.66) and 90% (OR 0.10; 95%CI 0.07-0.14) reduction in the risk of infection and hospitalization, respectively. Prior infection was associated with a 65% (OR 0.35; 95%CI 0.30-0.40) and 90% (OR 0.10; 95%CI 0.07-0.14) reduction in the risk of infection and hospitalization, respectively. Vaccinated and recovered subjects showed a 63% (OR 0.37; 95%CI 0.34-0.14) and 98% (OR 0.02; 95%CI 0-0.13) reduction in the risk of infection and hospitalization, respectively. Vaccination remains an essential public health tool for preventing severe forms of COVID-19. Our study shows that vaccination or previous infection has a strong protective effect against Sars-CoV-2 hospitalization. The protective role against infection appears to be present although with a lower efficacy rate than that presented in the RCTs.

摘要

我们的研究目的是确定先前 SARS-CoV-2 感染和接种疫苗对新感染和住院风险的联合保护作用。在意大利韦尔切利当地卫生部门 (LHU) 护理的 COVID-19 患者队列中进行了两项病例对照研究,一项用于估计感染风险,另一项用于估计住院风险。每例新发感染和住院均与最多 4 名无病患者相匹配,这些患者年龄、性别和索引日期(即对照)相同。研究对象从队列入组日期开始随访至疾病结局、随访结束或移民。接种疫苗分别使感染和住院风险降低 36%(OR 0.64;95%CI 0.62-0.66)和 90%(OR 0.10;95%CI 0.07-0.14)。先前感染分别使感染和住院风险降低 65%(OR 0.35;95%CI 0.30-0.40)和 90%(OR 0.10;95%CI 0.07-0.14)。已接种疫苗且已康复的患者的感染和住院风险分别降低 63%(OR 0.37;95%CI 0.34-0.14)和 98%(OR 0.02;95%CI 0-0.13)。接种疫苗仍然是预防 COVID-19 严重形式的重要公共卫生工具。我们的研究表明,接种疫苗或先前感染对 SARS-CoV-2 住院有很强的保护作用。针对感染的保护作用似乎存在,尽管效力比 RCT 中报告的要低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ed/9898230/2b2150050e8a/41598_2023_28129_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ed/9898230/2b2150050e8a/41598_2023_28129_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ed/9898230/2b2150050e8a/41598_2023_28129_Fig1_HTML.jpg

相似文献

1
Evaluation of the risk of SARS-CoV-2 infection and hospitalization in vaccinated and previously infected subjects based on real world data.基于真实世界数据评估接种疫苗和既往感染人群中 SARS-CoV-2 感染和住院的风险。
Sci Rep. 2023 Feb 3;13(1):2018. doi: 10.1038/s41598-023-28129-7.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州,2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
4
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性:一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
5
The Effect of Preventive Measures and Vaccination against SARS-CoV-2 on the Infection Risk, Treatment, and Hospitalization: A Cross-Sectional Study of Algeria.《预防措施和 SARS-CoV-2 疫苗接种对感染风险、治疗和住院的影响:阿尔及利亚的横断面研究》。
Viruses. 2022 Dec 12;14(12):2771. doi: 10.3390/v14122771.
6
Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.摩洛哥 BBIBP-CorV(Vero 细胞)灭活疫苗对 COVID-19 相关重症和危重症住院的长期有效性。
PLoS One. 2022 Dec 7;17(12):e0278546. doi: 10.1371/journal.pone.0278546. eCollection 2022.
7
The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.突破性 SARS-CoV-2 感染后不同疫苗类型的住院和死亡风险:医疗索赔数据的观察性研究。
JMIR Public Health Surveill. 2022 Nov 8;8(11):e38898. doi: 10.2196/38898.
8
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.2021 年 5 月 1 日至 7 月 25 日,加利福尼亚州洛杉矶县≥16 岁人群中,根据疫苗接种状况划分的 SARS-CoV-2 感染和住院情况。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
9
Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.高风险人群中突破性严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的完全接种疫苗者发生重症/危重症的比例和危险因素。
Clin Infect Dis. 2022 Aug 24;75(1):e849-e856. doi: 10.1093/cid/ciab1023.
10
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.分析利妥昔单抗的使用、利妥昔单抗与 SARS-CoV-2 疫苗接种之间的时间间隔以及多发性硬化症患者 COVID-19 住院或死亡的情况。
JAMA Netw Open. 2022 Dec 1;5(12):e2248664. doi: 10.1001/jamanetworkopen.2022.48664.

引用本文的文献

1
Predictors for vaccine hesitancy among nursing students in Namibia.纳米比亚护理专业学生疫苗犹豫的预测因素。
J Public Health Afr. 2024 Nov 5;15(1):683. doi: 10.4102/jphia.v15i1.683. eCollection 2024.
2
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.鼻内候选疫苗Mambisa和肌肉注射疫苗Abdala作为新冠康复者加强剂量的安全性和免疫原性:一项1-2期随机临床试验
Vaccines (Basel). 2024 Sep 1;12(9):1001. doi: 10.3390/vaccines12091001.
3
Prepandemic Physical Activity and Risk of COVID-19 Diagnosis and Hospitalization in Older Adults.

本文引用的文献

1
Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England.首次感染 SARS-CoV-2 对再次感染的保护作用:使用英格兰聚合酶链反应(PCR)检测数据的匹配回顾性队列研究。
Epidemiol Infect. 2022 May 24;150:e109. doi: 10.1017/S0950268822000966.
2
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
3
Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study.
疫情前的体力活动与老年人 COVID-19 诊断和住院风险的关系。
JAMA Netw Open. 2024 Feb 5;7(2):e2355808. doi: 10.1001/jamanetworkopen.2023.55808.
自然和诱导免疫对 delta 或 alpha 变异株 SARS-CoV-2 感染发生的保护作用:一项病例对照研究。
BMC Med. 2022 Feb 8;20(1):52. doi: 10.1186/s12916-022-02262-y.
4
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.SARS-CoV-2 奥密克戎免疫逃逸和受体结合的结构基础。
Science. 2022 Feb 25;375(6583):864-868. doi: 10.1126/science.abn8652. Epub 2022 Jan 25.
5
Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19.新型冠状病毒肺炎(COVID-19)疫苗接种在既往感染过新型冠状病毒的人群中的必要性。
Clin Infect Dis. 2022 Aug 24;75(1):e662-e671. doi: 10.1093/cid/ciac022.
6
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.基于信使核糖核酸的新冠病毒疫苗加强针可诱导针对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和免疫力。
Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6.
7
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.NVX-CoV2373 在美墨成年人群中的疗效和安全性。
N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15.
8
Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis.新冠康复者与完全接种疫苗者自然免疫的保护等效性:一项系统评价与汇总分析
Cureus. 2021 Oct 28;13(10):e19102. doi: 10.7759/cureus.19102. eCollection 2021 Oct.
9
A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection.一项关于既往 SARS-CoV-2 感染对重复感染保护作用的系统评价。
Eval Health Prof. 2021 Dec;44(4):327-332. doi: 10.1177/01632787211047932. Epub 2021 Sep 30.
10
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.Covid-19 疫苗在门诊和住院治疗环境中的有效性。
N Engl J Med. 2021 Oct 7;385(15):1355-1371. doi: 10.1056/NEJMoa2110362. Epub 2021 Sep 8.